New study finds iPhone displays ophthalmic images better than computers

New study finds iPhone displays ophthalmic images better than computers

Apple products have become particular popular in the medical community. A large percentage of eye care professionals are in possession of some sort of Apple device such as an iPhone, iPad, and often both. In a recent study, an iPhone 3G (two iPhone generations behind the current version) was compared to a desktop PC for the purpose of viewing images from patients. It was found that neuro-ophthalmologists rated images on the iPhone to be better than desktop images.

Read more at http://t.co/EfovU5dl

Advertisements

B + L’s Victus femtosecond laser cleared by FDA

Have you gotten a chance to read the August 8th issue of the Ophthalmology Times eReport? In this e-newsletter we released information on the Victus femtosecond laser receiving FDA approval, separate and combined cataract surgery, a protein that may block diabetic retinopathy damage (atypical protein kinase C), and more. Check out the articles in this issue below.

And please follow us on Twitter and Facebook

Femtosecond laser cleared by FDA

Bausch + Lomb (B + L) and Technolas Perfect Vision GmbH (TPV) have received 510(k) clearance from the FDA for a femtosecond laser platform (Victus), and it is now available for shipment within the United States. Read more

Combined or separate cataract, DSAEK procedures in Fuchs’ dystrophy?

In patients who present with both cataract and Fuchs’ endothelial corneal dystrophy, ophthalmologists have the option of performing cataract extraction alone or simultaneously with Descemet’s stripping automated endothelial keratoplasty (DSAEK), said Anthony Aldave, MD, at the 29th annual Current Concepts in Ophthalmology conference. Careful patient selection and informed consent are vital to choosing the proper approach. Read more

Cataract surgery reduces hip fracture risk

Patients who had cataract removal surgery were found to have a 16% decrease in the risk of hip fracture compared with patients who did not undergo the procedure, according to an observational study of more than 400,000 Medicare beneficiaries. Read more

Protein may block diabetic retinopathy damage

A protein that could “interrupt” the chain of events that causes retinal damage in diabetic retinopathy has been identified by researchers at the University of Michigan Kellogg Eye Center. The finding could lead to a therapy that targets two mechanisms at the root of the disease: inflammation and the weakening of the blood barrier that protects the retina. Read more

Jason Woody honored by EBAA

Jason Woody, president and chief executive officer of the Lions Eye Institute for Transplant & Research (LEITR), has received the Leonard Heise Award from the Eye Bank Association of America (EBAA). Read more

Prevent Blindness America Swing Fore Sight Golf Tournament supports eye programs

Sight-saving programs of Prevent Blindness America (PBA) will be supported by the 5th Annual Swing Fore Sight Golf Tournament, a four-person scramble set for Sept. 5 at the Royal Links Golf Club in Las Vegas. Read more

Bryan Lee, MD, JD, wins Vanguard Ophthalmology Society Scholar Award

Bryan S. Lee, MD, JD, a cornea, glaucoma, and refractive surgery fellow at Minnesota Eye Consultants, is the inaugural recipient of the Vanguard Ophthalmology Society Scholar Award. Read more

Haag-Streit, Reliance Medical Products name Ernest Cavin president, CEO

Ernest Cavin, MBA, DBA, has been named president and chief executive officer (CEO) of Haag-Streit USA and Reliance Medical Products, both based in Mason, OH. Read more

Sightpath expands social media efforts

Sightpath, a provider of mobile and fixed ophthalmic surgical products, has created a company blog, a Facebook page, a Twitter account, and a Vimeo channel, as well as a fortified LinkedIn profile. Read more

Check out Ophthalmology Times on Twitter and FacebookLaser, FDA, femtosecond

Optic neuritis treatments vary greatly for NMO and MS

Did you miss the July 18th issue of the Ophthalmology Times eReport? In this e-newsletter we released information on optic neuritis treatments, the Women in Ophthalmology (WIO) summer symposium, transcorneal electrical stimulation, and more. Check out the articles in this issue below.

Optic neuritis treatments vary greatly for NMO and MS

Optic neuritis in juvenile neuromyelitis optica (NMO) is a potentially blinding disease in pubescent and post-pubescent patients in the French West Indies. The treatments used for relapses of the disease and prevention are not well defined; however, they are very different from those used to treat patients with multiple sclerosis (MS). The critical need is to be able to differentiate between MS and NMO before treatment is initiated to preserve the visual and motor functions of those young patients, according to Rabih Hage, MD. Read more

Oral uveitis agent set for phase III trial

Patient enrollment has been completed for a phase III clinical trial of oral voclosporin (Luveniq, Lux Biosciences) for the treatment of non-infectious uveitis. Read more

Ophthalmic Women Leaders partners with Women in Ophthalmology for WIO Summer Symposium

Ophthalmic Women Leaders (OWL) is participating in the Women in Ophthalmology (WIO) summer symposium in Williamsburg, VA. Read more

RP studies look at implants and transcorneal electrical stimulation

Updates on research into therapies for both early- and late-stage retinitis pigmentosa (RP) were presented at the Retinal International World Congress. Read more

Dr. Osher receives latest Kelman Award at the Brazilian Congress of Ophthalmology

Ophthalmology Times Associate Medical Editor Robert H. Osher, MD, received the Kelman Award at the Brazilian Congress of Ophthalmology. Read more

University of Tennessee to feature lecture by glaucoma expert, M. Bruce Shields, MD

Glaucoma expert M. Bruce Shields, MD, will lecture at the Hamilton Eye Institute at the University of Tennessee (UT) Health Science Center Department of Ophthalmology. Read more

Topcon introduces new device, celebrates 80 years

Topcon Medical Systems has introduced a new computerized lensmeter (CL-300 Computerized Lensmeter) in U.S and Latin American markets. Read more

Optic-neuritis treatment modern medicine

Novel technology discriminates normal and ectatic eyes

Did you miss the July 11th issue of the Ophthalmology Times eReport? In this e-newsletter we released information on discriminating the difference between normal and biomechanically compromised or ectatic corneas, a new CPT code for the procedure used to implant miniature ophthalmic telescopes, new chair appointments at New York University and more. Check out the articles in this issue below.

Novel technology discriminates normal and ectatic eyes

Measurement of corneal parameters using dynamic ultra-high-speed Scheimpflug photography (CorVis ST, Oculus) is an effective method for discriminating between normal and biomechanically compromised or ectatic corneas, including very mild cases of forme fruste keratoconus (FFKC), according to the results of a retrospective study reported by Renato Ambrosio Jr., MD, PhD. Read more

Dispersive OVD gains FDA approval

The FDA has approved a dispersive ophthalmic viscosurgical device (OVD) (Healon EndoCoat OVD, Abbott Medical Optics) for use as a surgical aid in cataract extraction and IOL implantation. Read more

New CPT code for telescope implant

The American Medical Association (AMA) has released a new Current Procedural Terminology (CPT) code for the procedure used to implant miniature ophthalmic telescopes (Implantable Miniature Telescope [by Dr. Isaac Lipshitz], VisionCare Ophthalmic Technologies). Read more

Ocriplasmin BLA granted priority review

ThromboGenics NV has announced that the FDA has accepted the filing of the biologics license application (BLA) for ocriplasmin intravitreal injection 2.5 mg/ml and granted it priority review. The proposed indication of ocriplasmin intravitreal injection is for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole. Read more

Survey finds increased satisfaction with eye care

Satisfaction is increasing among patients who have a regular eye-care professional, according to a new survey. Read more

Drs. Galetta, Balcer to join NYU Langone

Steven L. Galetta, MD, has been appointed the Philip K. Moskowitz, MD, Professor and Chair of the department of neurology, and Laura Balcer, MD, MSCE, has been appointed vice chairwoman of the neurology department at the New York University (NYU) Langone Medical Center. The appointments are effective Nov. 1. Read more

How Bevacizumab Monotherapy Can Help Patients with ROP

Did you miss the July 5th issues of the Ophthalmology Times eReport? In this e-newsletter we released information on Bevacizumab (Avastin, Genentech) monotherapy for zone I retinopathy of prematurity, gender difference in presbyopia assistance, a scholarship for the “most beautiful eyes” and more. Check out the articles in this issue below.

Bevacizumab monotherapy shows potential for some patients with ROP

Bevacizumab (Avastin, Genentech) monotherapy for zone I retinopathy of prematurity (ROP) might have potential for treating pre-term infants who are in phase II of the pathogenesis of ROP. Read more

Gender differences may factor into presbyopia assistance

Ophthalmologists should consider gender differences in arm length and reading distance preferences when prescribing reading glasses or bifocal lenses, according to a recent study published in Investigative Ophthalmology & Visual Science. Such factors mean that women tend to desire assistance with presbyopia symptoms earlier than men do. Read more

George Bartley to become Ophthalmology editor in January

George B. Bartley, MD, will succeed Andrew P. Schachat, MD, as editor-in-chief of Ophthalmology, the American Academy of Ophthalmology’s (AAO’s) flagship journal, in January. Dr. Schachat has served in this capacity since 2003. Read more

Scholarship to be awarded for ‘most beautiful eyes’

A $10,000 educational scholarship is up for grabs in Prevent Blindness America’s (PBA’s) 2012 Most Beautiful Eyes Contest. Read more

Vitrectomy system gains 510(k) clearance

Synergetics USA Inc. has received 510(k) marketing clearance from the FDA for its proprietary vitrectomy system (VersaVIT). Read more

Acucela receives ‘Emerging Leader’ award

Acucela Inc. has been named as a recipient of the 2012 Emerging Leaders award from the Japan-U.S. Innovation Awards. Read more

NicOx, RPS sign worldwide licensing agreement

NicOx S.A. and Rapid Pathogen Screening Inc (RPS) have entered into a licensing agreement that gives NicOx access to RPS’s point-of-care ocular diagnostic tests. Read more

US FDA staff questions dosing of Lucentis eye drug

US FDA staff questions dosing of Lucentis eye drug

U.S. drug reviewers on Tuesday said Roche Holding AG’s eye drug Lucentis (ranibizumab injection) appeared to help patients with diabetic macular edema (DME), but questioned whether two different doses of the drug were equally safe and effective.

Staff from the U.S. Food and Drug Administration reviewed Lucentis ahead of an advisory panel of outside experts, which meets on Thursday to vote on whether to recommend approval of expanded use of the drug, which is administered monthly by injection.

Lucentis is already approved to treat wet age-related macular edema. It is also approved for macular edema following retinal vein occlusion (RVO).

Roche is hoping to expand its use to people with diabetic DME, the most common cause of moderate vision loss in patients with diabetes. There are currently no FDA-approved drugs for DME, a leading cause of vision loss among people of working age.

DME is currently treated by laser, which stops blood vessel leakage and can slow vision loss but rarely leads to vision improvement, Roche said.

In clinical trials Lucentis, made by Roche unit Genentech, helped patients see at least 15 extra letters on an eye chart, the primary goal of the study, FDA reviewers said.

People were also generally able to sustain the improvement in vision for at least 24 months — although those who took the 0.5 mg dose lost a bit of vision after the 18th month.

Both doses (0.5 and 0.3 mg) were generally safe, although there were slightly more deaths at the higher dose — 11 people who received the 0.5 mg dose died during the clinical trial, compared to seven taking the 0.3 mg dose and three receiving a sham injection. Each group contained 250 patients.

The FDA will ask advisers to recommend whether both doses of the drug should be approved for use against DME.

Copyright © 2012 Reuters Limited. All rights reserved.
Copyright 2012 Thomson Reuters. Click for Restrictions.

6 New Dispensing Updates for 2012

Ophthalmology Times, News, UpdatesCheck out our hand-picked updates for dispensing-related updates in 2012. Updates range from companies like Transitions and Nike to using tablets (like the iPad) and mobile devices.

Transitions releases extended dispensing guide, nominations open for Transitions Awards program

Transitions Optical Inc. has announced the availability of its expanded dispensing guide and is alerting the industry that the company is now accepting nominations for its Transitions Awards program. Read more

Alden Optical adds OOGP as authorized distributor of specialty lenses

Specialty contact lens maker Alden Optical Inc. announced recently that it has added OOGP to its network of authorized distributors. The addition of OOGP increases the reach of Alden’s portfolio of custom and specialty lenses.  Read more

Nike + Transitions = Nike MAX Transitions sunglasses

Nike Vision and Transitions Optical introduced new Nike MAX Transitions adaptive sunglasses at the Transitions Championship PGA TOUR event. Available in two colors, the lenses are responsive to changing light and specifically engineered for sport performance including golf, hiking and trail running. Read more

Digital lens fitting and dispensing technology for tablets

PFO Global and VSP Optics Group are co-developing digital lens fitting and dispensing technology for eye-care professionals to use on tablet or mobile computers. Together, the companies have jointly applied for patents on the technology, on which they have been in technical collaboration for the past year. Read more

Skechers introduces 10 styles for men, women, boys

Viva International Group introduced 10 styles to the Skechers Eyewear Spring/Summer 2012 collection. The new styles capture the sporty and vibrant feel of the brand. They consist of four ophthalmic styles for men, four for women and two for boys. Read more

Transitions makes available polycarbonate performance sun wear

KBco and Transitions Optical, Inc. have announced the availability of a polycarbonate performance sun lens called Xperio, which adapt to changing light conditions, improve contrast and reduce blinding glare from sunlight reflected off the surface of objects, water or snow making them ideal for outdoor activities such as fishing and water activities, running, hiking and mountain biking. Read more